Home › Major Depressive Disorder › Alabama
Major Depressive Disorder clinical trials in Alabama
15 studies for Major Depressive Disorder are looking for participants at sites in Alabama.
Cities in Alabama
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- University of Alabama at Birmingham - School of Medicine, Birmingham
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 1, 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Alabama at Birmingham, Huntsville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- UAB Psychiatry and Behavioral Neurology, Birmingham
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 8, 2026 · NCT07076407Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- University of Alabama at Birmingham - Dept. of Psychiatry, Birmingham
Recruiting
Ages 22 to 70 · All sexes · Updated Aug 28, 2026 · NCT06423430Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Birmingham VA Medical Center, Birmingham, AL, Birmingham
- Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 14, 2026 · NCT07226232NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Aug 3, 2026 · NCT06547489Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
RecruitingHealthy volunteers welcome
Ages 10 to 24 · All sexes · Updated Jul 13, 2026 · NCT05437588A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Harmonex /ID# 277517, Dothan
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997MicroRNA Correlates of Childhood Maltreatment and Suicidality
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Mar 30, 2026 · NCT04923685Using TMS to Understand Neural Processes of Social Motivation
- Auburn University, Auburn
Recruiting
Ages 25 to 50 · All sexes · Updated Mar 3, 2026 · NCT06274112Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #131, Birmingham
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jan 20, 2026 · NCT06633016From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.